Formulation and Evaluation of Nilotinib Nano-spanlastics for Cancer Treatment

Abstract

This research aims to develop and assess Nilotinib nano-spanlastics as an innovative drug delivery system, targeting the significant challenge of improving the cytotoxic efficacy and bioavailability of Nilotinib in cancer therapy. To address this issue, data on the physicochemical properties, release kinetics, and cytotoxic effects of the formulated nano-spanlastics across various cancer cell lines will be necessary. This dissertation examines the formulation and evaluation of Nilotinib nano-spanlastics as a novel drug delivery method designed to improve the cytotoxic effectiveness and bioavailability of Nilotinib in cancer therapy. The study rigorously investigates the physicochemical characteristics, release kinetics, and cytotoxic effects of the synthesized nano-spanlastics in different cancer cell lines, demonstrating that the innovative formulation substantially enhances the drug's bioavailability while preserving targeted cytotoxic activity. Essential findings demonstrate that nano-spanlastics promote superior drug release characteristics and have increased antiproliferative effects, especially in resistant cancer cells. The ramifications of these findings are significant, as they underscore the capacity of this sophisticated delivery system to enhance therapeutic effects in oncology, indicating a promising direction for more efficacious treatment protocols. This research advances the investigation of nanotechnology in medication formulation, offering insights that may guide future developments in cancer therapies and personalized medicine. This study addresses existing limits in Nilotinib distribution and efficacy, facilitating additional research into nanocarrier systems, which may revolutionize clinical procedures in cancer therapy and enhance patient quality of life